FDL176 + FDL169

FDL176 + FDL169 is an investigational oral combination therapy being developed for the treatment of cystic fibrosis, particularly in patients homozygous for the F508del-CFTR mutation. The combination consists of two small molecules with complementary mechanisms targeting the underlying defect in CFTR protein function. - **FDL169** acts as a CFTR corrector, designed to help misfolded CFTR protein (caused by mutations such as F508del) fold correctly and reach the cell surface. - **FDL176** is a CFTR potentiator that binds to the CFTR protein at the cell membrane and holds its channel open, increasing chloride ion transport across epithelial cells. The rationale for combining these agents is that correcting both folding/trafficking (with a corrector) and gating (with a potentiator) can synergistically improve overall CFTR function in people with cystic fibrosis[7][10][2]. Both drugs are under development by Flatley Discovery Lab.